We are building a spare change investment platform to help you invest in companies working on a cure for Alzheimer’s.

Imagine a world where drug companies are owned by millions of spare change investors committed to curing Alzheimer's

Join the cause, get on the list!
We'll keep you in the loop and you'll be the first to know when we launch!

Alzheimer’s must be cured!

Yet, most major pharmaceuticals have cut back on Alzheimer’s R&D as unprofitable, while smaller scientist led companies are left struggling for investment to develop promising scientific discoveries into a cure.


Alzheimer’s can be reversed in mice and many pathways to a cure have been discovered


Investment in companies working on a cure is scarce, stifling progress


A spare change investment platform to help millions invest in companies working on a cure for Alzheimer’s

InvestAcure has developed a formidable plan to end the roadblock imposed by insufficient capital to fund clinical trials necessary to discover effective cures for Alzheimer Disease. With so many major pharmaceutical companies leaving the space, it is even more imperative that we activate this approach immediately if we are to bring cures to families.

George Perry, Ph.D. Dean of College of Sciences - University of Texas at San Antonio & editor of the Journal of Alzheimer's Disease

Many advances in research are not pursued by larger drug companies whose economic models favor palliative care (long-term repeat drug sales) over cures and drugs over diagnostics while smaller companies struggle to attract investment. InvestAcure's Common Need Investment model has the potential to alleviate some of this investment bottleneck. 70 million US adults have a relative with Alzheimer's. If a small percentage of this affinity group invest their spare-change, billions of dollars will be freed to fund approaches that might otherwise be neglected.

David Weild Co-founder & Vice Chairman of InvestAcure, PBC and Former Chairman of the NASDAQ

We can cure Alzheimer’s in our mice every week, but when it comes to clinical research where real progress needs to be made to cure people, there is simply no funding available.

Hugo Geerts, Ph.D. Former head of Alzheimer's drug discovery at Johnson & Johnson Belgium

We can't afford to sit idly by as research is stalled by a profit-driven agenda. With InvestAcure, we have a real solution to speed the path to a cure, by transitioning ownership of drug companies to millions of spare change investors committed to curing Alzheimer's.

Julie A. Fleming Founder of Purple Sherpa

The idea of having millions of people impacted by Alzheimer's join together as spare change investors, who own stock in drug companies, represents an innovative and potentially game-changing solution to the "valley of death" problem in the pharmaceutical industry. If scaled to full potential, it can help ensure that smaller scientist led drug companies to have the investment and support of their shareholders needed to pursue the development of cutting edge scientific breakthroughs into lifesaving drugs. I’m excited to join the team and do my part in realizing this world-changing vision.

Yu-kai Chou Gamification pioneer, creator of the Octalysis Framework & author of Actionable Gamification. CXO - Head of UI/UX InvestAcure, PBC

When Harvey Pitt, former chairman of the SEC, visited MIT and mentioned InvestAcure as an example of a company using Finance for good, I was intrigued by the idea as it both spoke to my core values and was inspired by the research of my colleague, MIT Professor Andrew Lo, on the growing investment bottleneck stifling the development of lifesaving cures. I believe that Common Need Investment of spare change by millions committed to curing Alzheimer's is a potentially game-changing solution to that bottleneck. If successfully implemented, it can speed the development of lifesaving drugs and save countless lives. I'm excited to be an advisor to the InvestAcure team and do my part to help make this a reality.

Heidi V. Pickett Assistant Dean of the MIT Sloan Master of Finance Program

The InvestAcure Solution

Automatically round up transactions and invest just spare change in a portfolio of companies chosen by leading scientists

Sign up in under 5 minutes

Set up your InvestAcure investment account online and connect your credit cards


Spend like normal. Your day-to-day transactions are rounded up to the nearest dollar and set aside for investment


With the guidance of leading scientists, your spare change is invested in companies working on a cure for Alzheimer's


When drug companies are owned by millions of spare change investors committed to curing Alzheimer's....

Cure would be the
#1 priority

Billions in new investment to
explore every path
to a cure

Data from research and clinical trials
would be shared, so we could
build on each other's efforts and

As an InvestAcure investor, you actually own shares of the companies in your portfolio, so you’re part of the solution.

Seventy million Americans have a relative with Alzheimer's - every million spare change investors can mean $3 billion in investment over 5 years!
That would have 30X the impact of Bill Gates' recently publicized $100 million commitment to Alzheimer's research.

Meet Our Scientists

Your spare change will be invested in a portfolio of companies, chosen with the guidance of leading Alzheimer's researchers, based on their potential contribution to advancing the development of a cure.

Adeboye Adejare, PH.D Scientific Advisor

NIH and Alzheimer’s Association national panels. Over 50 publications, 5 patents, and more than 100 presentations at conferences.

Hugo Geerts, PH.D Scientific Advisor

CSO of In Silico Biosciences, headed Johnson & Johnson Alzheimer’s research and developed one of only 5 approved Alzheimer’s drugs.

Douglas J MacNeil, Ph.DScientific Advisor

A leading expert in early-stage drug discovery directed Exploratory & Translational Sciences at Merck, scientific board of Alzheimer's Drug Discovery Foundation, 144 research publications.

George Perry, PH.D Scientific Advisor

Editor-in-Chief of Journal of Alzheimer's, Dean UT-San Antonio, one of the top most-cited scientists in Neuroscience.

Lon Schneider, Ph.DScientific Advisor

Director of USC State of California Alzheimer’s Disease Center and the National Institute on Aging Alzheimer’s Disease Research Center. Editor-in-chief of Alzheimer’s & Dementia: Translational Research and Clinical Interventions.

Pierre Tariot, MD Scientific Advisor

Director of the Banner Alzheimer’s Institute. Over 350 scientific papers, including several leading to FDA approval of treatments for Alzheimer's.

J. Thomas Vaughan, Ph.D Scientific Advisor

Columbia University – Director of MR Research – 45 patents – pioneer in development of MRI technology for diagnosis of Alzheimer’s.

Paul Newhouse, MDScientific Advisor

Director, Center for Cognitive Medicine, Vanderbilt University.